Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 10 results
Filters: First Letter Of Title is P and Author is Bosch, Ronald J  [Clear All Filters]
Found 10 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

P

Lee AJ, Bosch RJ, Evans SR, et al. "Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen." J. Neurovirol.. 2015;21(2):210-8.
Stewart P, Cachafeiro A, Napravnik S, et al. "Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay." J. Clin. Virol.. 2010;49(3):198-204.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Evans SR, Ellis RJ, Chen H, et al. "Peripheral neuropathy in HIV: prevalence and risk factors." AIDS. 2011;25(7):919-28.
Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJ. "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia." Antivir. Ther. (Lond.). 2015;20(1):73-6.
Bruggeman LA, O'Toole JF, Ross MD, et al. "Plasma apolipoprotein L1 levels do not correlate with CKD." J. Am. Soc. Nephrol.. 2014;25(3):634-44.
Zheng L, Bosch RJ, Chan ES, et al. "Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy." Antivir. Ther. (Lond.). 2013;18(1):39-43.
Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. "Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2007;44(3):268-77.
Robertson KR, Smurzynski M, Parsons TD, et al. "The prevalence and incidence of neurocognitive impairment in the HAART era." AIDS. 2007;21(14):1915-21.
Dykes C, A Mukherjee L, Bosch RJ, Connick E, Volberding PA, Demeter LM. "Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371." J. Acquir. Immune Defic. Syndr.. 2010;55(1):132-4.